Introduction
============

Influenza is an acute illness caused by influenza viruses. During seasonal epidemics, large numbers of influenza infections occur in all age groups. In most individuals, influenza is a self-limiting illness, but serious secondary complications appear in some of those infected with the influenza viruses. Influenza virus infection-related morbidity and mortality is a serious human health concern worldwide, affecting health of populations and economies worldwide. The illness may result in hospitalisation, overwhelming hospitals and causing excess influenza health-related deaths \[[@r1]\]. Worldwide, annual epidemics are estimated to result in ca 3 to 5 million cases of severe illness and ca 250,000 to 500,000 deaths \[[@r2]\]. Individuals who are elderly, especially those with comorbidities, are particularly at risk for influenza-related complications and frequently require hospitalisation. In an American study carried out in the 2005/06 through 2013/14 seasons, 89% of all influenza-associated deaths were in people aged ≥ 65 years \[[@r3]\]. A recent French study estimated that 11% of all-cause deaths in elderly individuals during the influenza season were attributable to influenza \[[@r4]\]. However, mortality is just the tip of the iceberg in terms of disease and the economic burden, and hospitalisation is also an important outcome that should be considered \[[@r5]\].

The capacity of influenza viruses to undergo gradual antigenic change in their surface antigens is a challenge for vaccination against seasonal influenza. Annual administration of the seasonal influenza vaccine, especially in those known to be at high risk of serious complications as a result of influenza, is the focus of current efforts to reduce the disease impact \[[@r1]\]. In the 2013/14 season, the trivalent inactivated vaccine administered in Spain and in all the northern hemisphere, contained an A/California/7/2009(H1N1)pdm-09-like virus, an A(H3N2) virus antigenically similar to the cell-propagated prototype virus A/Victoria/361/2011 and a B/Massachusetts/2/2011-like virus. For the 2014/15 season, the vaccine composition only changed the A/Victoria/361/2011 component to the A/Texas/50/2012 component, an antigenically similar virus.

Various factors affect influenza vaccine effectiveness (VE). One main factor is the antigenic similarity or dissimilarity between circulating strains and vaccine strains: VE decreases with increasing antigenic distance between vaccine components and circulating strains \[[@r6]\]. There was no mismatch in 2013/14 for the A(H1N1)pdm09 and A(H3N2) components but in 2014/15, some degree of mismatch for the A(H3N2) circulating strain was observed \[[@r7],[@r8]\]. Another factor is the influenza illness rate, which may vary substantially from year to year; in years with low rates, the power of some studies to detect significant VE may be compromised \[[@r9]\]. Therefore, studies including more than one season are recommended in order to estimate VE.

The aim of this study was to assess the effectiveness of influenza vaccination in preventing hospitalisation due to laboratory-confirmed influenza in individuals aged ≥ 65 years during two influenza seasons (2013/14 and 2014/15) in Spain.

Methods
=======

Study design
------------

We carried out a multicentre case--control study in 20 major hospitals from seven of 17 Spanish regions (Andalusia, the Basque Country, Catalonia, Castile and Leon, Madrid, Navarra and Valencian Community), covering 1,444,688 individuals aged ≥ 65 years and representing 16.8% of the Spanish population in this age group. Cases and corresponding controls admitted to participating hospitals between December 2013 and March 2015 were recruited.

Selection of cases and controls
-------------------------------

We selected patients aged ≥ 65 years who were hospitalised for at least 24 hours with laboratory-confirmed (PCR, culture or immunofluorescence) influenza virus infection.

For each case, up to three matched controls from among patients aged ≥ 65 years with unplanned hospital admission due to causes other than influenza or acute respiratory disease were selected. Controls were matched with each case according to sex, age (± 3 years) and date of hospitalisation (± 10 days). They were selected from patients admitted to the internal medicine, general surgery, otorhinolaryngology, ophthalmology, dermatology or traumatology services wards. Patients referred from nursing homes and those who did not provide written informed consent were excluded.

Data collection
---------------

The following demographic variables and pre-existing medical conditions were recorded: age, sex, marital status, educational level, smoking and high alcohol consumption (\> 40 g/day for men and \> 24 g/day for women), number of hospital visits during the last year, the Barthel Index as a measurement of limitations in activity (ranging from 0 (complete dependence) to 100 (complete independence)), chronic obstructive pulmonary disease (COPD), chronic respiratory failure, history of pneumonia during the last two years, other lung diseases, neoplasia, transplantation, immunosuppressive treatment, asplenia, diabetes mellitus, renal failure, nephrotic syndrome, autoimmune disease, AIDS, asymptomatic HIV infection, congestive heart disease, disabling neurological disease, obesity (body mass index ≥ 30 kg/m^2^), chronic liver disease, haemoglobinopathy or anaemia, cognitive dysfunction, convulsions and neuromuscular disease. Information on influenza vaccination in the current and previous season, and information on pneumococcal vaccination was collected.

Cases were considered vaccinated with the current influenza vaccine or pneumococcal vaccine if they had received a dose of the vaccine ≥ 14 days before symptom onset. Controls were considered vaccinated if they had received a dose of the influenza vaccine ≥ 14 days before the onset of symptoms of the matched case. Influenza vaccination in the previous season in cases and controls was defined as administration of the seasonal influenza vaccine during the preceding influenza season.

Statistical analysis
--------------------

A bivariate comparison for matched data of demographic variables and medical conditions between cases and controls was made using McNemar's test. A two-tailed distribution was assumed for all p values.

A univariate conditional logistic regression model was used to estimate the crude VE in preventing influenza hospitalisation. Propensity score (PS) analysis was used to evaluate the adjusted VE. The PS was created using a logistic regression model with influenza vaccination status as the outcome and demographic variables, medical conditions and functional status as independent variables. The PS was used as a continuous covariate in a final conditional logistic regression model.

Using the formula *VE = (1 − OR) × 100*, VE was calculated globally, by season, for the presence of high-risk medical conditions, for age groups, for type/subtype of influenza virus and for each category of vaccine exposure: vaccinated only in current season, only in prior season, in both seasons, and unvaccinated in both seasons as the reference group.

The analysis was performed using the SPSS version 23 statistical package and the R version 3.3.0 statistical software \[[@r10]\].

Ethical considerations
----------------------

All data collected were treated as confidential, in strict observance of legislation on observational studies. The study was approved by the ethics committees of the participating hospitals. Written informed consent was obtained from all patients included in the study.

Results
=======

A total of 728 cases and 1,826 controls were included in the study. The distribution of cases and controls according to demographic variables, medical conditions and vaccination history is shown in [Table 1](#t1){ref-type="table"}. A total of 359 cases (49.3%) and 1,053 controls (57.7%) had received influenza vaccination. Of the 728 cases, 433 were from the 2013/14 season and 295 were from the 2014/15 season. Of the 433 cases from the 2013/14 season, 429 (99.1%) were infected with influenza A virus (59.8% were A(H1N1)pdm09, 30.5% were A(H3N2) and 8.8% were unsubtyped), two cases were infected with influenza B virus and two cases were missing data for type and subtype. Of the 295 cases from the 2014/15 season, 258 (87.5%) were infected with influenza A virus (22.4% were A(H1N1)pdm09, 42.0% were A(H3N2) and 23.1% were unsubtyped) and 37 (12.5%) were infected with influenza B virus.

###### Distribution of influenza cases and controls aged ≥ 65 years according to demographic variables, medical conditions and history of vaccination, Spain, influenza seasons 2013/14 and 2014/15

  --------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                      Cases\      Controls\     Crude OR       95% CI       p value                
                                                       (n = 728)   (n = 1,826)                                                      
  ---------------------------------------------------- ----------- ------------- ---------- ---------------- --------- ------------ ----------
  **Age group**                                                                                                                     

  65--79 years                                         411         56.5          1,016      57.0             Ref       Ref          0.50

  ≥ 80 years                                           317         43.5          810        43.0             0.89      0.64--1.24   

  **Sex**                                                                                                                           

  Female                                               343         47.1          884        48.4             NA        NA           NA

  Male                                                 385         52.9          942        51.6             NA        NA           NA

  **Marital status**                                                                                                                

  Married/cohabiting                                   450         61.9          1,020      56.0             Ref       Ref          Ref

  Single                                               39          5.4           145        8.0              0.57      0.39--0.83   0.004

  Widowed                                              217         29.8          615        33.8             0.76      0.61--0.95   0.02

  Separated/divorced                                   21          2.9           42         2.3              1.17      0.68--2.00   0.57

  **Educational level**                                                                                                             

  Without or primary                                   560         77.0          1,349      74.9             Ref       Ref          0.07

  Secondary or higher                                  167         23.0          453        25.1             0.81      0.64--1.01   

  **Barthel Index^a^**                                                                                                              

  0--90**^a^**                                         276         37.9          796        43.6             0.79      0.64--0.96   0.02

  \> 90**^a^**                                         452         62.1          1,028      56.4             Ref       Ref          

  **Smoking status**                                                                                                                

  No smoker                                            383         52.6          1,057      57.9             Ref       Ref          0.01

  Smoker/ex-smoker                                     345         47.4          769        42.1             1.39      1.09--1.77   

  **High alcohol consumption^b^**                                                                                                   

  Yes                                                  16          2.2           53         2.9              0.77      0.43--1.38   0.38

  No                                                   712         97.8          1,772      97.1             Ref       Ref          

  **Number of hospital visits during the past year**                                                                                

  0--2                                                 403         56.1          916        50.6             Ref       Ref          0.05

  ≥ 3                                                  316         43.9          896        49.4             0.82      0.67--1.00   

  **High-risk medical conditions**                                                                                                  

  No                                                   104         14.3          386        21.1             Ref       Ref          \< 0.001

  Yes                                                  624         85.7          1,440      78.9             1.73      1.35--2.22   

  **Current-season influenza vaccine received**                                                                                     

  Yes                                                  359         49.3          1,053      57.7             0.73      0.61--0.87   \< 0.001

  No                                                   369         50.7          773        42.3             Ref       Ref          

  **Previous-season influenza vaccine received**                                                                                    

  Yes                                                  376         51.6          1,054      57.7             0.78      0.66--0.93   0.005

  No                                                   352         48.4          772        42.3             Ref       Ref          

  **Pneumococcal vaccine received**                                                                                                 

  Yes                                                  372         51.1          836        45.8             1.20      0.99--1.46   0.06

  No                                                   356         48.9          990        54.2             Ref       Ref          
  --------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; NA: not applicable; OR: odds ratio; Ref: reference group for comparison.

^a^ The Barthel Index is a measurement of limitations in activity, ranging from 0 (complete dependence) to 100 (complete independence).

**^b^** High alcohol consumption defined as \> 40 g/day for men and \> 24 g/day for women.

Most cases (85.7%) and controls (78.9%) had high-risk medical conditions ([Table 2](#t2){ref-type="table"}).

###### Distribution of influenza cases and controls aged ≥ 65 years according to comorbidities, Spain, influenza seasons 2013/14 and 2014/15

  -------------------------------------------------------------------------------------------------------------------------------
  Characteristics                        Cases\      Controls\     Crude OR       95% CI       p value                 
                                         (n = 728)   (n = 1,826)                                                       
  -------------------------------------- ----------- ------------- ---------- ---------------- --------- ------------- ----------
  **High-risk medical conditions**                                                                                     

  COPD                                   194         26.6          218        11.9             3.03      2.37--3.88    \< 0.001

  Chronic respiratory failure            119         16.3          208        11.4             1.64      1.26--2.14    \< 0.001

  Pneumonia past 2 years                 91          12.5          104        5.7              2.40      1.77--3.26    \< 0.001

  Other lung disease                     238         32.7          380        20.8             1.88      1.54--2.30    \< 0.001

  Cardiovascular disease                 224         30.8          651        35.7             0.84      0.68--1.03    0.09

  Diabetes mellitus                      235         32.3          666        36.5             0.89      0.74--1.07    0.21

  Renal failure with hemodialysis        16          2.2           31         1.7              1.27      0.68--2.37    0.46

  Hemaglobinopathy or anaemia            89          12.2          306        16.8             0.68      0.52--0.88    0.004

  AIDS                                   1           0.1           2          0.1              1.30      0.12--14.51   0.83

  Asymptomatic HIV infection             3           0.4           1          0.1              9.00      0.94--86.52   0.06

  Neurological disease                   51          7.0           136        7.4              0.93      0.64--1.33    0.93

  Obesity (BMI  ≥ 30 kg/m^2^)            174         23.9          370        20.3             1.25      1.01--1.56    0.04

  **Non high-risk medical conditions**                                                                                 

  Solid organ neoplasia                  103         14.1          348        19.1             0.67      0.52--0.85    0.001

  Haematologic neoplasia                 39          5.4           40         2.2              2.57      1.62--4.07    \< 0.001

  Transplantation                        22          3.0           10         0.5              5.52      2.52--12.09   \< 0.001

  Immunosuppressive treatment            35          4.8           67         3.7              1.35      0.87--2.08    0.18

  Oral corticosteroid therapy            44          6.0           43         2.4              2.54      1.62--3.97    \< 0.001

  Asplenia                               2           0.3           8          0.4              0.66      0.14--3.11    0.60

  Renal failure without hemodialysis     135         18.5          341        18.7             1.01      0.80--1.26    0.94

  Nephrotic syndrome                     7           1.0           14         0.8              1.14      0.45--2.88    0.78

  Autoimmune disease                     47          6.5           96         5.3              1.38      0.94--2.03    0.10

  Chronic liver disease                  28          3.8           95         5.2              0.76      0.49--1.18    0.22

  Cognitive dysfunction                  76          10.4          205        11.2             0.92      0.68--1.23    0.92

  Neuromuscular disease                  24          3.3           53         2.9              1.16      0.70--1.93    0.55

  Convulsions                            8           1.1           23         1.3              0.84      0.37--1.92    0.69
  -------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; OR: odds ratio.

The overall adjusted VE against influenza hospitalisation in individuals aged ≥ 65 years was 36% (95% CI: 22--47), without relevant differences between seasons (34%, 95% CI: 10--52 in 2013/14 and 37%, 95% CI: 19--51 in 2014/15) ([Table 3](#t3){ref-type="table"}). The adjusted VE was greater, but not significantly different, in patients without high-risk medical conditions (51%, 95% CI: 15--71) and in patients aged 65--79 years (39%, 95% CI: 20--53). Adjusted VE was 37% (95% CI: 23--48) for all influenza A viruses, 49% (95% CI: 32--62) for influenza A(H1N1)pdm09 and 26% (95% CI: −3 to 47) for influenza A(H3N2). Protection against influenza B was lower (VE 18%, 95% CI: −145 to 73), but the number of cases was very low (statistical power: 10%).

###### Crude and adjusted influenza vaccine effectiveness against hospitalisation because of influenza in individuals aged ≥ 65 years according to influenza season, presence or absence of high-risk medical conditions, case age and type/subtype of influenza virus, Spain, influenza seasons 2013/14 and 2014/15

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                              Cases\         \%     Controls\      \%     Crude\              95% CI       p value    Adjusted\           95% CI       p value
                                         vaccinated/n          vaccinated/n          vaccine\                                    vaccine\                         
                                                                                     effectiveness                               effectiveness                    
  -------------------------------------- -------------- ------ -------------- ------ --------------- ---------------- ---------- --------------- ---------------- ----------
  **All**                                359/728        49.3   1,053/1,826    57.7   27%             13--39           \< 0.001   36%             22--47           \< 0.001

  **2013/14 season**                     208/433        48.0   602/1,038      58.0   31%             13--45           0.002      37%             19--51           \< 0.001

  **2014/15 season**                     151/295        51.2   451/788        57.2   21%             −3 to 40         0.08       34%             10--52           0.01

  **Non high-risk medical conditions**   42/104         40.4   159/255        62.4   54%             27--71           0.001      51%             15--71           0.01

  **High-risk medical conditions**       317/624        50.8   894/1,571      56.9   21%             7--32            0.01       30%             14--44           \< 0.001

  **65--79 years of age**                183/411        44.5   561/1,040      53.9   29%             11--44           0.003      39%             20--53           \< 0.001

   **≥ 80 years of age**                 176/317        55.5   492/786        62.6   24%             0--42            0.05       34%             12--51           0.01

  **Influenza A**                        334/687        48.6   991/1,717      57.7   30%             16--41           \< 0.001   37%             23--48           \< 0.001

  **Influenza A(H1N1)pdm09**             139/325        42.8   464/823        56.4   41%             24--55           \< 0.001   49%             32--62           \< 0.001

  **Influenza A(H3N2)**                  138/256        53.9   393/652        60.3   22%             −5 to 42         0.10       26%             −3 to 47         0.08^a^

  **Influenza B**                        24/39          61.5   58/103         56.3   −35%            −187 to 36       0.43       18%             −145 to 73       0.72^b^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval

^a^ Statistical power: 74%.

^b^ Statistical power: 10%.

Adjusted VE against hospitalisation was 41% (95% CI: 16--59) among those only vaccinated in the current season and 42% (95% CI: 28--54) among those vaccinated in both the current and previous season. VE among those only vaccinated in the previous season only was 24% (95% CI: −6 to 45) ([Table 4](#t4){ref-type="table"}).

###### Crude and adjusted influenza vaccine effectiveness against hospitalisation because of influenza in individuals aged ≥ 65 years according to current and previous influenza vaccination, Spain, influenza seasons 2013/14 and 2014/15

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccination status                       Cases\      Controls\     Crude\              95% CI       p value   Adjusted\           95% CI       p value              
                                           (n = 728)   (n = 1,826)   vaccine\                                   vaccine\                                              
                                                                     effectiveness                              effectiveness                                         
  ---------------------------------------- ----------- ------------- --------------- ---------------- --------- --------------- ---------------- --------- ---------- ----------
  **Vaccinated in current season only**    52          7.1           160             8.8              35%       7--54           0.02             41%       16--59     0.004

  **Vaccinated in previous season only**   69          9.5           161             8.8              13%       −20 to 37       0.39             24%       −6 to 45   0.11^a^

  **Vaccinated in both seasons**           307         42.2          893             48.9             28%       13--41          0.001            42%       28--54     \< 0.001

  **Not vaccinated**                       300         41.2          612             33.5             Ref       Ref             Ref              Ref       Ref        Ref
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; Ref: reference group for comparison.

^a^ Statistical power: 54%.

Discussion
==========

The results of this study over two seasons, one with predominant circulation of influenza A (H1N1)pdm09 and one with A(H3N2) predominance, show overall VE against hospitalisation in individuals aged ≥ 65 years was 36% (95% CI: 22--47).

Some studies investigating the prevention of influenza hospitalisation among individuals who are elderly show greater VE \[[@r11],[@r12]\]. In a German study using the screening method, VE in preventing confirmed influenza hospitalisation in individuals aged ≥ 60 years varied between 62% in the 2011/12 season, when the predominant influenza virus strain was A(H3N2), and 83% in the 2010/11 season, when the predominant strain was A(H1N1)pdm09 \[[@r11]\]. However, these levels of VE might be an overestimate because information on comorbidities was not available to adjust them by \[[@r13]\]. A Spanish case--control study for the 2014/15 season, when the predominant strain was A(H3N2), using test-negative controls in 10 hospitals not included in the present study found a VE of 40% (95% CI: 13--59) in terms of preventing hospital admissions in patients 65 years of age and older \[[@r14]\]. A 2014 New Zealand study, also using a test-negative control design, found a VE of 21% (95% CI: −82 to 66) for influenza-related hospitalisation in patients aged ≥ 65 years \[[@r15]\].

An American test-negative study by Petrie et al. \[[@r16]\] during the 2014/15 season found a VE of 48% (95% CI: −33 to 80) in people aged ≥ 65 years, but the number of individuals included was lower than in the present study. A Chinese test-negative study in people aged \> 60 years during the two seasons included in our study, but with a lower number of individuals than in our study, found a point estimate of VE of 27% (95% CI: −114 to 75) during the 2013/14 season. However, no effectiveness was observed in the 2014/15 season \[[@r17]\].

The possible influence of increasing age on VE has been investigated. In our study, adjusted VE against hospitalisations was 39% (95% CI: 20--53) in patients aged 65--79 years and 34% (95% CI: 12--51) in patients aged ≥ 80 years. Decreasing effectiveness has been linked to advanced age in different studies \[[@r12],[@r18],[@r19]\]. Senescence diminishes immunity to influenza infections and the response to vaccination, possibly explaining the lower VE in elderly individuals than in the general population \[[@r20]\].

In terms of analysing VE in older age groups, the German study by Remschmidt et al. found that the VE point estimate against laboratory-confirmed influenza was greater in individuals aged 60--69 years than in older individuals in the 2011/12 season, but the opposite was observed in the 2010/11 season \[[@r11]\]. More research is needed to assess this matter.

In our study, VE was 30% (95% CI: 14--44) in patients with high-risk medical conditions, which was lower than that found in patients without these conditions. Similar results were obtained by other studies \[[@r16],[@r21]\]. In contrast, a 2014/15 Canadian test-negative case--control study of individuals aged ≥1 year by Skowronski et al. \[[@r22]\] did not find a lower age-adjusted VE in patients with comorbidities (16%, 95% CI: −28 to 44) than in patients without comorbidities (6%, 95% CI: −20 to 27). Comorbidities, like age, are strongly associated with a lack of response to vaccination \[[@r23]\]. In fact, one of the major mechanisms through which vaccination is thought to reduce mortality is by blunting influenza-triggered exacerbations of underlying diseases \[[@r9]\]. However, despite the limited VE, the benefits of vaccination may be greater in patients with comorbidities because influenza is associated with a higher risk of severe disease and death in these individuals \[[@r24]\].

Similar to the results of other studies of VE in elderly individuals \[[@r11],[@r25]\], the present study found that VE for subtype A(H1N1)pdm09 was greater (49%, 95% CI: 32--62) than that for subtype A(H3N2) (26%, 95% CI: −3 to 47).

Small, non-significant VE differences were found according to season. In the 2013/14 season, an antigenic mismatch was observed in the B virus component but the A(H1N1)pdm09 and A(H3N2) strains circulating were analogous to the seasonal vaccine strains \[[@r7]\]. However, in some Spanish regions, specific mutations of A(H1N1) and A(H3N2) strains associated with low VE and outbreaks in institutions were found \[[@r26]\]. In the 2014/15 season, mismatched A(H3N2) strains circulated widely around the world \[[@r27]\], but only accounted for 60% of influenza A virus isolates in Spain \[[@r8]\]. This might explain why no relevant differences were found in VE in these two influenza seasons.

In our study, VE in individuals vaccinated only in the current season was similar to that of individuals vaccinated in both the current and previous seasons (41%, 95% CI: 16--59 and 42%, 95% CI: 28--54, respectively), which does not support interference between current and previous vaccination. Three 2014/15 influenza season studies carried out on populations of various ages \[[@r16],[@r22],[@r28]\] reported that vaccination in the previous and current season may diminish VE only in the current season, suggesting negative interference from prior vaccination when the antigenic distance between the vaccine and circulating strains is large but the antigenic distance between vaccine components in consecutive seasons is small \[[@r22]\]. The effects of the various combinations of agent-host factors involved in this phenomenon remain unclear and more research is required to determine their influence on vaccine-induced influenza virus immunity in elderly individuals. However, in agreement with Neuzil \[[@r29]\], we consider that the current policy of administering the influenza vaccine every year should be maintained in the meantime. As the most-vulnerable elderly individuals are those with the most advanced age because they have a higher risk of hospitalisation and death compared with healthy elderly individuals aged 65--75 years \[[@r20]\], seasonal influenza vaccination programs in all elderly individuals should be reinforced.

This study has strengths and limitations. Strengths of this study are the matching design, the high number of covariates recorded and the fact that the vaccination status was obtained by consulting hospital records, vaccination cards and primary health registers.

The limitations include the fact that controls were not systematically swabbed and therefore they may, theoretically, have been infected with influenza virus. However, controls were patients with unplanned admission to hospital because of causes other than influenza or acute respiratory disease, and it seems unlikely that selection bias could invalidate our results. A possible confounder is the functional status; however, we included the Barthel Index in the propensity score and therefore this limitation is reasonably controlled for. Likewise, it is important to consider the weeks with influenza activity in the analysis, but because cases and controls were matched by admission date, we believe this is unlikely to invalidate the results. Another possible limitation is that cases and controls were recruited in 20 major hospitals, but as these hospitals cover 16.8% of the Spanish population aged ≥ 65 years we believe that the study is representative of the older Spanish population. Also, we have not collected information on patients' influenza-like illness in previous seasons, but previous episodes of influenza does not usually act as a confounding factor that needs to be controlled for in studies evaluating influenza VE \[[@r30]\]. Finally, the low statistical power in the investigation of VE against influenza B virus because of the very low number of cases in the two seasons studied was another limitation.

In conclusion, the results of this study show that influenza vaccination was effective in preventing hospitalisations because of influenza in individuals who are elderly. The point estimates of the adjusted VE were highest in patients without high-risk medical conditions, in patients in the 65--79 years of age group and against the influenza A(H1N1)pdm09 subtype compared with the A(H3N2) subtype, although the 95% confidence limits overlapped. Finally, we found that VE was similar between vaccination only in the current season and vaccination in both the current and the previous seasons.
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